reason report
trust process ad car-t dilut near term lift
bottom line yesterday celgen announc
agreement buy partner
juno celgen stock
trade line market day previous
under-perform day deal first discuss
press view transact posit particularli
compar invest celgen made past
might made doubl area celgen
alreadi strong platform make sens particularli given
long durat asset like high barrier
competit entri develop market
today updat market compani model
celgen includ first forecast car-t product
revenu forecast increas modestli begin
beyond expens forecast increas significantli
near term result ep estim celgen come
higher base
probabl adjust revenu earn contribut addit
new program celgen model base chang
forecast reduc target price
maintain outperform rate celgen stock expect
complet addit research better understand develop
risk competit timelin profil commerci opportun
celgen expand portfolio car-t treatment opportun
revenu includ leerink forecast valuat
po updat forecast includ reach
market myeloma forecast revenu
grow quickli reach
give po po adjust
revenu contribut increas
forecast particip
multipl myeloma car-t market celgene/bluebird still
retain greatest share
leerink revenu forecast increas includ
exclud celgen right partner car-t
product compani model valuat given uncertainti
time scope competit profil adopt trajectori
program today announc inevit cost
absorb consolid program believ
appropri includ revenu program first time
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
forecast match celgen seem us includ
optimist assumpt given earli stage develop uncertain
time uncertainti give celgene/juno
preferenti market share dlbcl indic although give
greater share bcma/mm set model
appli po dlbcl cll
non-po adjust basi forecast revenu
start build
po adjust basi ad revenu
forecast
leerink revenu forecast increas longer
term addit compani
forecast celgen result small increas revenu forecast
compani becom signific
mid exhibit adjust revenu forecast compani
recent consensu
higher consensu later year mainli base posit
contribut ozanimod continu growth revlimid sale
base chang forecast estim
reduc target price celgen reiter
current outperform rate celgen stock expect follow
updat research competit profil revenu
cost margin valuat impact juno program
conjunct updat car-t model probability-of-
success assumpt adjust yescarta sale forecast
gilead mp led materi chang
total compani revenu estim chang valuat
price gilead stock
exhibit effect car-t model updat celg
signific expens adjust account fund cost juno program
expens forecast celgen increas significantli account full cost
fund develop juno program well fund
cost build valid run car-t manufactur facil
celgen program expect full cost celgen facil expens
prior approv celgen first car-t program gradual shift
report cost good car-t program indic market
launch forecast celgen increas
later year sg forecast also increas partial
account increment technic administr overhead associ juno
acquisit partial account increment commerci invest expect celgen
make support launch car-t product sg forecast increas
higher later year initi expect celgen
car-t program neg gross margin given burdensom overhead
manufactur facil time expect gross margin improv
revenu run rate compani success advanc
car-t product commerci thu increas po oper
margin would like improv given rel fix cost much manufactur
treatment expect celgen provid detail commentari perhap guidanc
cost impact acquisit futur confer call lastli expect celgen
captur modest tax save juno nol reduc report tax rate
almost mean expect earn dilut
neutral adjust ep estim recent
consensu higher later year expect celgen
oper margin dip year recov later year
investor unlik endors immedi celgen revenu forecast
controversi element celgen announc revenu forecast
total sale juno car-t therapeut product significantli consensu
leerink forecast compani continu explain basi forecast
call specif celgen believ uniqu characterist allow
deploy mani center exist car-t approach gilead yescarta
nvss kymriah main differ celgen emphas follow convers
better toler specif rate sever cytokin releas syndrom
rate sever neurotox
celgen believ profil similar profil mani chemo-
immunotherapi regimen routin use hematolog malign regimen
first administ tertiari care set routin given outpati
commun set thu celgen forecast base assumpt number
treatment site car-t treatment dlbcl expand two three-fold compar
current estim potenti tertiari treatment center captur major
increment treatment center patient
compani assum discount treatment cost car-t
result increas competit intens better toler attend lower
medic cost offset net price eros potenti even allow premium price
rival includ compani base case forecast celgen explain
revenu forecast almost dlbcl assum car-t treatment move
earlier line treatment forecast includ contribut
pursu small revenu contribut cll stage believ
suffici inform clinic experi confid profil
suffici differ competitor result kind expans domin market
share celgen thesi plausibl enough remain valid larger patient number
peer-review present public
longer term celgen expect combin agent car-t treatment
enhanc efficaci expect announc studi combin one
checkpoint antibodi well potenti form target immunotherapi
celgen expect car-t treatment myeloma also high unchang
transact celgen manag convinc car-t treatment disrupt
multipl myeloma potenti advanc rapidli line even displac exist
standard care autolog stem cell transplant pivot trial
get underway limit data avail far find hard
declar adopt broad deep celgen suggest
acknowledg data promis albeit hand patient
celgen commit maintain earn guidanc
one question celgen outlook concern impact acquisit
car-t product near term longer term profit seem clear near
term profit suffer celgen absorb develop
manufactur commerci cost juno organ advanc commerci
car-t treatment compani expect pro forma ebit margin dip
compar lower prior forecast expect
compani ebit margin recov almost level neg
effect compani gross margin also trend neg start
commerci first car-t program sg also like somewhat higher
compani boost commerci organ provid direct support patient
identif apheresi transport re-administr car-t treatment overal still
see compani prior pro forma ep guidanc achiev given modestli higher
revenu expect profit still lower previous forecast
anti-trust clearanc remain risk given investor expect
one outstand question transact whether ftc allow
celgen consolid amount differ bcma-direct car-t treatment
multipl myeloma compani state us legal due dilig suggest
clearanc like base number competitor alreadi activ treatment categori
estim earli stage juno car-t treatment enter
clinic develop believ would materi neg celgen
restrict compani abil develop manufactur commerci
second gener bcma program hand expect
program remain low doubt whether juno celgen investor much valu
associ program stage believ divestitur alter ownership
either satisfi ftc concern meet contractu oblig would
materi harm celgen valuat outlook
juno deal impact bioscienc deal announc estim
celgen would end net debt estim non-gaap ebitda
calcul celgen leverag ratio exit celgen maintain
net cash posit much earli rais approxim debt
fund recepto acquisit ozanimod result celgen leverag ratio increas
neg positon leverag celgen de-lev
substanti sinc recepto acquisit leverag ratio fallen
result two acquisit estim leverag ratio
quarter assum ebitda base compani guidanc howev
cash flow revlimid core product year bring celgen leverag ratio
end base model includ share repurchas
assumpt celgen would target leverag ratio post-recepto
peak believ celgen still balanc sheet capac enact
busi develop activ howev celgen will extend leverag ratio
compani could complet deal rang though believ
unlik exhibit
addit car-t total hematolog revenu forecast celgen increas
total product revenu increas year total
revenu forecast recent consensu estim although
other estim certainli also review manufactur cell process
associ cost increas cost good expens increas
mid-upp singl digit percentag
expect celgen conduct multipl late stage clinic trial therapi sg
expens forecast increas per year due cost associ
commerci therapi oper margin decreas
mani increment expens realiz prior level subsequ year
estim net oper loss acquir juno result one-tim decreas
celgen effect tax rate pro-forma ep decreas
pre-juno revenu margin guidanc depreci net debt ratio leveragecelg-juno addit ebitda acquisit net debt ratio debt capacitypost-rcpt leverag net debt addit debt leverag net debt addit debt leverag net debt addit debt leverag mm healthcar
prior transact becom
ep neutral new ep estim recent consensu
result chang impli target price base earn multipl decreas
dcf valuat decreas overal price target
averag multipl earn multipl sale discount cash flow
analysi previous
conjunct celgen car-t model updat also refresh estim
gilead yescarta non-hodgkin lymphoma nhl po po cll
estim major global yescarta revenu deriv
nhl indic given year exhibit estim sale
grow long-term forecast peak
exhibit yescarta global sale mm indic
compar previou forecast new estim gilead yescarta unchang
lower compar prior howev increas mid-term
estim similarli increas long-term estim
exhibit
result chang yescarta estim remain consensu year
near-term recent consensu long-term
recent consensu exhibit total forecast sale
larg unchang due updat total revenu estim remain recent
consensu non-
gaap ep estim also unchang updat higher recent
consensu consensu
sourc leerink partner research compani file zack factset consensu
sourc leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
price target celgen corp celg stock rate outperform
celgen transform treatment one form cancer myeloma aim
transform treatment other futur core technolog develop
small molecul drug base chemistri immunomodulatori drug imid form
variant thalidomid drug proven tremend effect myeloma
today compani gener revenu hematolog product sale almost
myeloma imid product franchis continu grow volume-
limit gener revlimid entri given structur characterist market
posit myeloma celgen hope revlimid similar util lymphoma
anoth indic equal greater size see drug less advantag
posit diseas beyond imid celgen invest right broad array novel
technolog product hematolog oncolog inflammatori diseas potenti
product remain seen shape critic year assess
valu like return invest
price target celgen celg base simpl averag three approach
believ reason basi valu stock today approach simpl
price earn multipl compar high growth larg cap medic product drug
devic compani present valu base price sale multipl peer coverag
discount cash flow dcf analysi use averag peer distress larg cap biopharma
compani rhhbi sni multipl consensu ep
appli ep estim celgen support one-year price target
use exclus matur biotech price sale multipl
revenu appli revenu estim give fair valu
share lastli dcf use estim compani current wacc appli
period cash flow assum annual declin cash flow
termin valu adjust cash debt give present valu per share
averag three approach current price target
risk view outlook valuat celgen includ major chang price
reimburs coverag revlimid compani main product today risk includ
commerci develop disappoint compani diversifi program otezla
ozanimod lastli challeng compani revlimid patent posit would
view neg investor would larg dilut acquisit research invest
could undermin compani oper profit return invest capit
opportun greater upsid current forecast includ duplic earli clinic trial
result ozanimod expand trial inflammatori bowel diseas success develop
commerci program compani collabor juno juno
earli impress result acceler develop
compani antibodi durvalumab partner astrazeneca azn revlimid
potenti lymphoma alreadi includ model probabl success adjust basi
better-than-expect result on-going phase trial suggest revlimid
becom standard care diseas would also offer signific upsid
current forecast valuat
rate gilead stock market perform price target downgrad stock
sept chang hepat market forecast compani
erod sharpli sooner anticip specif see patient volum
declin steadili initi peak market revenu yield per patient continu
trend neg base decreas treatment durat increas discount
manufactur compet govern commerci contract posit forecast total
hcv revenu gilead declin
declin like acceler beyond better competit hcv regimen come
market outlook compani hiv busi remain posit suffici
off-set unusu dynam hcv busi rel modest contribut
product offer littl mitig effect boom bust hcv forecast
total hcv revenu fall short current consensu like drive
signific neg margin trend given hcv extrem strong profit hope
gilead intern develop pipelin busi develop invest could off-set
risk opportun appear arriv late littl valu high
price gilead manag miss sever attract transact opportun
paid high premium enter oncolog market cellular therapi without declar
competit advantag gilead valuat current all-tim low recov rel
peer earn declin potenti continu neg revis substanti
termin uncertainti make hard us recommend stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough
consensu forward earn multipl slow-growth medic product stock
teva appli ep estim gilead give price
altern appli slow-grow large-cap medic product us pharma spec
pharma eu pharma revenu multipl revenu estim deriv impli
valu impli one year price target use sum part valuat
exist franchis get price consist primarili price compani
hiv franchis hcv product lastli dcf use forecast free cash
flow appli growth rate termin cash flow forecast
discount valu back present wacc give present valu
averag four approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip
pipelin asset bictegravir hiv filgotinib ra ibd advanc develop
commerci assum oper margin declin peak
fall would advers affect forecast valuat opportun better
perform valu expect includ delay limit develop
profil adopt competit hiv hcv product success develop
underappreci element compani portfolio momelotinib selonsertib
entospletinib stronger-than-expect convers current hiv patient gilead next
otezla apremilast po adjust indic dev
million
vidaza pharmion mid march
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target celgen
method price base mature/end patent life larg cap biopharma ep multipl
appli celg ep rhhbi sni
leerink forma ep estim celg
price
equiti
number period
method present valu base price sale multipl matur larg cap biotech
averag price sale larg cap biotech multipl
impli celg market cap mm estimate sale
anticip share count mm
number period
method leerink probabl adjust dcf adjust net wacc termin
growth rate expiri revlimid patent
averag method
sourc leerink partner estim compani file factset
million
darunavir/c/f-taf royalti
darunavir/c/f-taf royalti
leerink partner research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method trough price earn multipl larg cap ex growth biopharma compani
trough larg cap valu healthcar stock multipl ep teva
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
leerink revenu estim gilead
comp ex growth larg cap revenu multipl us pharma spec pharma
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
leerink partner research compani file factset
